What Can Patients With HFpEF Gain From Iron Supplementation?
A recent study investigated the effects of intravenous ferric carboxymaltose (FCM) on patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency. While FCM normalized blood iron levels in many patients, it did not lead to improvements in exercise hemodynamics or myocardial energy metabolism. The study suggests potential benefits in right ventricular function and exercise tolerance, despite its limitations.
- ▪The study included 45 patients with HFpEF and iron deficiency, with 42 completing the trial.
- ▪FCM treatment resolved iron deficiency in 15 of 20 recipients and significantly increased ferritin and transferrin saturation levels.
- ▪Despite improvements in right ventricular ejection fraction and walk distance, FCM did not change exercise hemodynamics or cardiac energy measures.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/what-can-patients-hfpef-gain-iron-supplementation-2026a1000gy8?src=rss |
| Publication time | Tue, 26 May 2026 08:00:00 EDT |
| Retrieval time | 2026-05-26T12:07:48.662Z |
| Last seen | 2026-05-26T12:07:48.662Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | xfO8WDE2LxiZ |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency without anaemia, intravenous ferric carboxymaltose (FCM) normalised blood iron levels but did not improve exercise haemodynamics or myocardial energy metabolism.METHODOLOGY:Researchers conducted a phase 2, double-blind, randomized clinical trial (IRON-HFpEF) at two Dutch centres to assess whether intravenous FCM could improve cardiovascular function and exercise tolerance in patients with HFpEF and iron deficiency without anaemia.They included 45 patients (mean age, 69 years; 78% women) between August 2020 and February 2023, with 42 patients completing the trial.Patients were randomly assigned to receive FCM dosed according to body weight and haemoglobin levels (median dose, 1000 mg) or…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
